Vericel (NASDAQ:VCEL – Get Free Report) and Gain Therapeutics (NASDAQ:GANX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.
Institutional and Insider Ownership
12.0% of Gain Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Vericel and Gain Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $306.30 million | 6.74 | $16.52 million | $0.47 | 85.74 |
| Gain Therapeutics | $50,000.00 | 1,230.65 | -$20.16 million | ($0.50) | -2.82 |
Vericel has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Vericel and Gain Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 2 | 4 | 0 | 2.67 |
| Gain Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Vericel currently has a consensus target price of $58.40, indicating a potential upside of 44.91%. Gain Therapeutics has a consensus target price of $7.67, indicating a potential upside of 443.74%. Given Gain Therapeutics’ higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Vericel.
Profitability
This table compares Vericel and Gain Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 7.91% | 6.91% | 5.02% |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
Volatility & Risk
Vericel has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Summary
Vericel beats Gain Therapeutics on 10 of the 13 factors compared between the two stocks.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
